Geothermal Developer Ignis H2 Energy Raises $12.5M in Series A First Close
Funds to Advance Exploration Projects in USA, Turkey, Indonesia & Italy
Ignis H2 Energy Inc. (“Ignis Energy”), a geothermal exploration and development startup, announced today the successful first closing of its Series A funding round, securing $12.5 million from a consortium of investors, including leading funds and private individuals. The funding round was led by alfa8 and includes a commitment from drilling contractor Nabors Industries, alongside investments from existing shareholders, private individuals, and family offices.
Advancing a Global, Risk-Balanced Geothermal Portfolio
Unlike other startups in the geothermal industry, Ignis Energy does not rely on a single technology or opportunity. Instead, it manages a risk-balanced portfolio of geothermal power-producing opportunities across high-enthalpy environments worldwide. By leveraging proven technologies and insights from a distinguished panel of geothermal experts, Ignis Energy diversifies risk while ensuring a steady pipeline of sustainable energy projects. The company has already secured promising geothermal opportunities in Turkey, Alaska, California, Nevada, and Italy.
Driven by a mission to provide affordable, reliable, and sustainable baseload geothermal energy, Ignis Energy integrates extensive expertise from the oil and gas sector into geothermal exploration and development. The company is pioneering the use of cutting-edge machine learning models to predict, locate, and explore geothermal resources more efficiently, leading to better drilling outcomes and lower project risk. With a portfolio spanning multiple geographies and geological formations, Ignis Energy is targeting the development of one gigawatt of documented producible geothermal reserves by 2030.
Strategic Investors Committed to Geothermal Innovation
Alfa8: Investing in a Sustainable Future -- alfa8 is committed to advancing technologies that accelerate the global shift toward sustainable energy solutions. With a strong focus on geothermal innovation and next-generation renewables, the firm backs forward-thinking pioneers redefining the energy landscape while ensuring environmental stewardship. Erin Glenn, COO of alfa8, emphasized the firm’s strategic approach: “As a patient capital investor, alfa8 is dedicated to funding transformative ventures that address the energy crisis, drive the adoption of geothermal energy, and push the frontiers of maritime decarbonization and critical sustainability initiatives.”
Nabors Industries: Driving the Future of Geothermal Exploration -- With a presence in over 20 countries, Nabors Industries is a leading provider of advanced technology for the energy industry. By leveraging its core competencies, particularly in drilling, engineering, automation, data science and manufacturing, Nabors aims to innovate the future of energy and enable the transition to a lower carbon world. Spearheading advancements in geothermal technologies and projects is a key focus of Nabors’ energy transition strategy.
Guillermo Sierra, VP, Strategic Initiatives at Nabors, asserted that “Ignis Energy will be a strong addition to our geothermal investment portfolio as we seek to catalyze breakthrough technologies and collaborate with experienced operators to deliver energy without compromise. We believe Ignis’ project portfolio and management team is best-in-class and we are pleased to collaborate with them on near-term projects and support their long-term growth, which we expect will include additional collaboration with Nabors’ other geothermal technology ventures.”
Richard Calleri, CEO of Ignis Energy stated “we are a geothermal exploration and development company focused on building a risk-balanced portfolio of geothermal power plants across key global markets. By combining proven technologies, expert knowledge, and advanced data analytics, Ignis Energy is unlocking the full potential of geothermal resources and accelerating the transition to a cleaner, more sustainable energy future.”
Marcus Oesterberg, COO of Ignis Energy added that “our approach is technology agnostic with a focus on high enthalpy and predominantly traditional geothermal resources that can be developed with today’s technology for power production.”
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219707620/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom